Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

Stack, W A, Mann, S D, Roy, A J, Heath, P, Sopwith, M, Freeman, J, Holmes, G, Long, R, Forbes, A ORCID: https://orcid.org/0000-0001-7416-9843 and Kamm, M A (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. The Lancet, 349 (9051). pp. 521-524. ISSN 0140-6736

Full text not available from this repository. (Request a copy)

Abstract

Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.

Item Type:	Article
Uncontrolled Keywords:	adolescent,adult,aged,antibodies,c-reactive protein,crohn disease,double-blind method,glycoproteins,humans,middle aged,placebos,remission induction,tumor necrosis factor-alpha,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:56
Last Modified:	24 Oct 2022 06:35
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49550
DOI:	10.1016/S0140-6736(97)80083-9

Actions (login required)

View Item